Day: September 19, 2025

OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that new translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Ovarian Cancer Research, being held September 19-21, 2025, in Denver, Colorado. IMNN-001, based on IMUNON’s proprietary TheraPlas® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector incorporated into a novel nanoparticle delivery system,...

CARY, N.C., Sept. 19, 2025 (GLOBE NEWSWIRE) — Fathom Holdings Inc. (Nasdaq: FTHM), a national, technology-driven real estate services platform, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price of $2.00 per share. The Company also has granted the underwriter of the offering a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions. After the underwriting discount and anticipated expenses, the Company expects to receive net proceeds of approximately $5.4 million, not including exercise of the overallotment option. The offering is expected to close on September 22, 2025, subject to customary closing conditions. The Company intends to use the net proceeds from the offering...

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) — Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading technology conglomerate in the Latin American SaaS sector, today announced that Chief Executive Officer Pierre Schurmann will participate in the keynote presentation titled “LatAm Giants Mastering Expansion: The Global Playbook” at Brazil Investment Week in London, UK on September 30, 2025. With a career that includes over 600 startup investments and a legacy of pioneering ventures in tech, marketing, and executive networking, Mr. Schurmann exemplifies the innovative force driving Brazil’s business ecosystem. His leadership at Nuvini reflects a bold strategy of scaling high-potential SaaS companies across Latin America, aligning with the summit’s broader theme of unlocking cross-border investment opportunities...

Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offering a non-surgical treatment option for infants, young children and adults PFIC is a rare and life-threatening liver disease that affects an estimated 100 children and infants in Japan.1Paris, France – 19 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for Bylvay® (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC). PFIC is a group of rare genetic disorders in which bile acid accumulates in the liver, leading to progressive liver damage and potentially liver failure. The condition...

Series  RIKB 42 0217Settlement Date  09/24/2025Total Amount Allocated (MM)  1,643All Bids Awarded At (Price / Yield)  78.600 / 6.680Total Number of Bids Received  17Total Amount of All Bids Received (MM)  3,243Total Number of Successful Bids  9Number of Bids Allocated in Full  9Lowest Price / Highest Yield Allocated  78.600 / 6.680Highest Price / Lowest Yield Allocated  79.471 / 6.580Lowest Price / Highest Yield Allocated in Full  78.600 / 6.680Weighted Average of Successful Bids (Price/Yield)  78.769 / 6.660Best Bid (Price / Yield)  79.471 / 6.580Worst Bid (Price / Yield)  78.400 / 6.710Weighted Average of All Bids Received (Price / Yield)  78.630 / 6.680Percentage Partial Allocation (Approximate)  100.00 %Bid to Cover Ratio  1.97

Recent Purchases include 1,087 ETH at an Average Price of $4,598  Charlotte, NC, Sept. 19, 2025 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company”), today announced that its current ETH position increased to 49,715 ETH as of September 18, 2025, following a series of additional purchases and reflecting the positive impact of the Company’s initial staking rewards. The Company’s total ETH holdings are 49,715 representing approximately $229 million in aggregate value (assuming $4,598 price of ETH per Bloomberg as of 4:15pm ET). The Company’s strategic plan is to be the largest ETH holder in the Ethereum network. “Ethereum stands as the premier programmable asset for institutional reserves, and we’re executing on our strategy to be the dominant corporate stakeholder,” said Maja Vujinovic, CEO of Digital Assets, FG...

DAYTONA BEACH, Fla., Sept. 19, 2025 (GLOBE NEWSWIRE) — TopBuild Corp., (NYSE:BLD) a leading installer of insulation and commercial roofing and a specialty distributor of insulation and related building material products to the construction industry in the United States and Canada, will host an Investor Day in New York City on Tuesday, December 9, 2025, beginning at 8:00 a.m. ET. TopBuild President and CEO Robert Buck, CFO Rob Kuhns, and other members of the senior leadership team will present an in-depth overview of the Company, its proven business model, growth drivers, capital allocation strategy and long-term financial targets. The event will also include Q&A sessions and lunch, where in-person attendees will have the opportunity to interact with management and learn more about the business. A formal invitation to register...

MONTREAL, Sept. 19, 2025 (GLOBE NEWSWIRE) — In his role as Senior Director, Global Risk Management and Insurance at Bombardier, Daniel Desjardins has shaped the risk management and insurance landscape, as well as Bombardier’s journey, in profound ways. This week, the Risk and Insurance Management Society (RIMS) recognized that impact by presenting him with the Donald M. Stuart award, Canada’s highest honour within the risk management field. Few individuals leave a legacy as enduring as Daniel’s. Over the past 40 years, he has consistently demonstrated leadership, strong work ethic and an unwavering commitment to excellence—both within the insurance community and across Bombardier. Daniel played a pivotal role in Bombardier’s successful turnaround, offering unmatched expertise, strategic clarity and steady guidance during a defining...

REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare. The biosimilars approved for the Japanese market are AVT03, a biosimilar to Ranmark® (denosumab), AVT05, a biosimilar to Simponi® (golimumab) and AVT06, a biosimilar to Eylea® (aflibercept). Based on publicly available information, AVT05 is the first golimumab biosimilar to be approved for sale in major markets globally. “We are thrilled to receive marketing approvals for three additional biosimilars in Japan, after our...

REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare. The biosimilars approved for the Japanese market are AVT03, a biosimilar to Ranmark® (denosumab), AVT05, a biosimilar to Simponi® (golimumab) and AVT06, a biosimilar to Eylea® (aflibercept). Based on publicly available information, AVT05 is the first golimumab biosimilar to be approved for sale in major markets globally. “We are thrilled to receive marketing approvals for three additional biosimilars in Japan, after our successful launch last...